首页> 外文OA文献 >The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
【2h】

The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.

机译:IVADo方案-对患有转移性软组织肉瘤的儿童进行异环磷酰胺,长春新碱,放线菌素D和阿霉素的试验研究:代表欧洲儿科软组织肉瘤研究小组进行的试验研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The role of doxorubicin (Doxo) as part of multidrug regimens used to treat children with soft tissue sarcoma (STS) is controversial. To evaluate the feasibility of combining Doxo with the well established ifosfamide, vincristine, and actinomycin D (IVA) regimen, the Italian STS Committee performed a pilot study on a series of children with metastatic STS.\udMETHODS:\udBetween July 2002 and February 2004, 29 evaluable patients were enrolled in this study; 19 patients had rhabdomyosarcoma, 5 patients had peripheral neuroectodermal tumor, and 5 patients had other types of STS. The IVA-Doxo (IVADo) regimen included ifosfamide 3 g/m(2) on Days 1 and 2, vincristine 1.5 mg/m(2) on Day 1, actinomycin D 1.5 mg/m(2) on Day 1, and Doxo 30 mg/m(2) on Days 1 and 2. Three courses of IVADo were to be administered in the initial part of treatment and analyzed for toxicity and tumor response.\udRESULTS:\udOverall, 92 cycles were delivered. Major regimen-related toxicity was myelosuppression, with Grade 4 neutropenia in 67% of cycles and fever and neutropenia in 37% of cycles. Nonhematologic toxicity included Grade 3-4 mucositis (6.5% of cycles), constipation (9.7%), and peripheral neuropathy (6.5%). Other manifestations of major toxicity were venoocclusive disease and seizures, which occurred in one patient each. All but 1 patient with a malignant schwannoma showed some degree of tumor volume reduction; however, considering only complete and partial remissions, the response rate was 76% (+/- 7.9%).\udCONCLUSIONS:\udThe intensive IVADo regimen was effective against pediatric STS with acceptable toxicity. This combination will be investigated in high-risk patients with rhabdomyosarcoma in a randomized trial launched by the European pediatric Soft tissue sarcoma Study Group.
机译:阿霉素(Doxo)作为用于治疗儿童软组织肉瘤(STS)的多种药物疗法的一部分的作用是有争议的。为了评估将Doxo与完善的异环磷酰胺,长春新碱和放线菌素D(IVA)方案结合的可行性,意大利STS委员会对一系列转移性STS儿童进行了一项初步研究。\ udMETHODS:\ ud在2002年7月至2004年2月之间这项研究招募了29名可评估患者;横纹肌肉瘤19例,周围神经外胚层肿瘤5例,其他类型的STS 5例。 IVA-Doxo(IVADo)方案在第1和第2天服用异环磷酰胺3 g / m(2),在第1天服用长春新碱1.5 mg / m(2),第1天放线菌素D 1.5 mg / m(2)和Doxo在第1天和第2天,剂量为30 mg / m(2)。在治疗的最初阶段将分三个疗程进行IVADo的治疗,并分析其毒性和肿瘤反应。\ udRESULTS:\ ud总体而言,已完成92个周期。与方案相关的主要毒性是骨髓抑制,其中67%的周期为4级中性粒细胞减少,而37%的周期为发热和中性粒细胞减少。非血液学毒性包括3-4级粘膜炎(周期的6.5%),便秘(9.7%)和周围神经病变(6.5%)。主要毒性的其他表现为静脉闭塞性疾病和癫痫发作,每例患者中均发生一次。除1例恶性神经鞘瘤患者外,所有患者均显示出一定程度的肿瘤缩小。但是,仅考虑完全缓解和部分缓解,缓解率为76%(+/- 7.9%)。\ ud结论:\ ud强化IVADo方案可有效治疗儿童STS,且毒性可接受。欧洲儿科软组织肉瘤研究小组发起的一项随机试验将在高危横纹肌肉瘤患者中研究这种组合。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号